PRKDC and neoplasm: In this study, we generated cancer cell line drug combination screens of six kinase inhibitors, including two ATM inhibitors (M3541 and M407616), three ATR inhibitors (berzosertib17,18, gartisertib19, M177420), and one DNA-PK inhibitor (peposertib21,22) against 87 anti-cancer drugs of a wide range of mode-of-actions on 22 ~ 62 cancer cell lines across 12 tissues (or tumor types), forming a total of 17,912 combination treatment experiments.